Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Acquired by Steamboat Capital Partners LLC

Steamboat Capital Partners LLC increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 43.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 249,751 shares of the biopharmaceutical company's stock after purchasing an additional 75,890 shares during the quarter. Halozyme Therapeutics accounts for about 3.7% of Steamboat Capital Partners LLC's investment portfolio, making the stock its 8th largest holding. Steamboat Capital Partners LLC owned approximately 0.20% of Halozyme Therapeutics worth $11,941,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Shay Capital LLC acquired a new stake in Halozyme Therapeutics during the 4th quarter worth approximately $215,000. Rafferty Asset Management LLC grew its position in Halozyme Therapeutics by 16.4% in the fourth quarter. Rafferty Asset Management LLC now owns 219,392 shares of the biopharmaceutical company's stock valued at $10,489,000 after acquiring an additional 30,852 shares in the last quarter. Point72 Europe London LLP acquired a new stake in Halozyme Therapeutics in the fourth quarter valued at approximately $1,403,000. ProShare Advisors LLC grew its position in Halozyme Therapeutics by 28.8% in the fourth quarter. ProShare Advisors LLC now owns 47,114 shares of the biopharmaceutical company's stock valued at $2,253,000 after acquiring an additional 10,531 shares in the last quarter. Finally, Panoramic Capital LLC acquired a new stake in Halozyme Therapeutics in the fourth quarter valued at approximately $2,621,000. Institutional investors and hedge funds own 97.79% of the company's stock.

Halozyme Therapeutics Stock Performance

HALO traded up $0.48 during trading hours on Wednesday, hitting $53.93. 1,967,953 shares of the stock were exchanged, compared to its average volume of 1,615,109. The stock has a 50-day simple moving average of $60.22 and a 200-day simple moving average of $55.92. Halozyme Therapeutics, Inc. has a 12 month low of $42.01 and a 12 month high of $70.51. The stock has a market cap of $6.65 billion, a price-to-earnings ratio of 15.72, a price-to-earnings-growth ratio of 0.42 and a beta of 1.26. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.13. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The firm had revenue of $264.86 million for the quarter, compared to analysts' expectations of $231.21 million. During the same period last year, the business posted $0.79 earnings per share. The firm's revenue for the quarter was up 35.2% on a year-over-year basis. Analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Transactions at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 4,497 shares of the stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $60.37, for a total value of $271,483.89. Following the completion of the transaction, the director now owns 28,611 shares in the company, valued at $1,727,246.07. This represents a 13.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the transaction, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $10,126,499.68. The trade was a 0.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 21,697 shares of company stock valued at $1,276,552. 2.40% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Wells Fargo & Company increased their price objective on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a research report on Wednesday, May 7th. Leerink Partnrs downgraded shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Tuesday, May 13th. Morgan Stanley downgraded shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and lowered their price objective for the company from $73.00 to $62.00 in a research report on Wednesday, May 14th. JPMorgan Chase & Co. increased their price objective on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a research report on Monday, April 21st. Finally, Leerink Partners cut Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 target price for the company. in a research note on Tuesday, May 13th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $61.90.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.